Johnson & Johnson's five most important drugs in 2017
January 25, 2017 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Johnson & Johnson's sales of consumer goods and medical devices amount to billions of dollars, but the company's pharmaceutical industry will be one of the areas most likely to promote the company's growth in 2017. The following are the reasons why Infinerazumab, rivaroxaban, Ibrutinib, Darzalex, and Eudragitum may have the greatest impact on Johnson & Johnson's 2017 income.
1. Infliximab
In the third quarter of last year, the autoimmune drug, Infliximab, had sales of $1.8 billion, more than 20% of the company's third quarter global drug sales ($8.4 billion), but this could be a problem because Pfizer has a generic Inflectra was approved in the United States last November. In the United States, Infinera's sales in the United States are $1.2 billion per quarter, and now it has to compete with Inflectra, but considering that Inflectra's price is 15% cheaper, the sales of Infineximab will definitely decline, and it is difficult to rise again.
In the company's third quarter conference call, executives told investors that infinex's market share in other regions that compete with generics is still 90%. Obviously, if Infinex is able to maintain a similar market share in the US, the impact of Inflectra is not large, but it is difficult to determine whether Johnson & Johnson will maintain its market share by lowering prices, and it is difficult to determine medical staff. Will patients be encouraged to try Inflectra to determine the best drug? Given these uncertainties, investors may be paying close attention to changes in sales of Infliximab in the next four quarters.
2, rivaroxaban
With a third-quarter sales of 529 million, the anti-coagulant is one of Johnson & Johnson's best-selling drugs, and despite its annual sales of $2 billion, the drug still has room to rise. In the third quarter of last year, the total market share of the rivaroxaban prescription market was only 17.5%, an increase of 1.7% year-on-year. Its growth was mainly due to the decline in the market share of the most commonly used anticoagulant warfarin, which was in the third quarter of 2015. The share fell from 62% to 55%. Since entering the market in 2011, Rivarsap’s annual sales growth rate is double-digit, so this growth rate may be maintained in the future.
3, Ibrutinib
Johnson & Johnson and Abbott have pushed Ibrutini into the market. Although Johnson & Johnson and Abbott are now parting ways, Ibrutinib still makes an important contribution to the growth of Johnson & Johnson sales. Its sales in the third quarter increased by 92% to $349 million. The increased use of this drug makes it the main drug for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstom giant cell cytokines, which will continue to increase sales this year.
4, Darzalex
Three months after its introduction to the market, Darzalex has become the most commonly used four-line treatment prescription for multiple myeloma, with annual sales of billions of dollars. Johnson & Johnson has listed the drug as one of 10 new drugs with a potential for billions of sales, but it also depends on expanding the drug's indication range as soon as possible.
In February of this year, Johnson & Johnson can determine whether they can take a big step toward this goal. Last year, a clinical trial showed that Darzalex combined with the most commonly used multiple myeloma drug lenalidomide to significantly improve patient symptoms. Johnson & Johnson submitted to the FDA in August to approve the combination therapy as a second-line therapy for multiple myeloma. In batches, Darzalex's sales will surge, as the target for sales of lenalidomide this year is $8 billion.
5, Utech monoclonal antibody
Utek's third-quarter sales rose to $814 million, an increase of 32.8% year-on-year. Considering that the drug was approved for the treatment of Crohn's disease last year, the drug's income will continue to increase this year. . Utech monoclonal antibody is the first biological preparation approved for the treatment of Crohn's disease. It targets IL-12 and IL-21. Considering that the drug is effective and the mechanism of action is relatively new, Johnson & Johnson considers this drug Will soon be favored by doctors and patients. According to statistics, 70%-80% of patients with Crohn's disease treated with anti-TNFs do not respond well to the drug within one year. Considering that Utec monoclonal antibody is better, its sales in the next decade will increase to 50%, which management believes will increase the drug's sales by about $500 million.
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.apipepdites.com